Jennifer Chan, MD, MPH, discussed the findings from the phase 3 CABINET trial leading to the FDA approval of cabozantinib in patients with neuroendocrine tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback